182 related articles for article (PubMed ID: 32209084)
1. Phase-I trial of survivin inhibition with EZN-3042 in dogs with spontaneous lymphoma.
Thamm DH; Joseph JK; Rose BJ; Meuten TK; Weishaar KM
BMC Vet Res; 2020 Mar; 16(1):97. PubMed ID: 32209084
[TBL] [Abstract][Full Text] [Related]
2. Survivin inhibition via EZN-3042 in canine lymphoma and osteosarcoma.
Shoeneman JK; Ehrhart EJ; Charles JB; Thamm DH
Vet Comp Oncol; 2016 Jun; 14(2):e45-57. PubMed ID: 24923332
[TBL] [Abstract][Full Text] [Related]
3. Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide.
Sapra P; Wang M; Bandaru R; Zhao H; Greenberger LM; Horak ID
Nucleosides Nucleotides Nucleic Acids; 2010 Feb; 29(2):97-112. PubMed ID: 20391197
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.
Raetz EA; Morrison D; Romanos-Sirakis E; Gaynon P; Sposto R; Bhojwani D; Bostrom BC; Brown P; Eckroth E; Cassar J; Malvar J; Buchbinder A; Carroll WL
J Pediatr Hematol Oncol; 2014 Aug; 36(6):458-63. PubMed ID: 24276047
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of survivin expression in untreated and relapsed canine lymphoma.
Rebhun RB; Lana SE; Ehrhart EJ; Charles JB; Thamm DH
J Vet Intern Med; 2008; 22(4):989-95. PubMed ID: 18647159
[TBL] [Abstract][Full Text] [Related]
6. First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer.
Bianchini D; Omlin A; Pezaro C; Lorente D; Ferraldeschi R; Mukherji D; Crespo M; Figueiredo I; Miranda S; Riisnaes R; Zivi A; Buchbinder A; Rathkopf DE; Attard G; Scher HI; de Bono J; Danila DC
Br J Cancer; 2013 Nov; 109(10):2579-86. PubMed ID: 24169353
[TBL] [Abstract][Full Text] [Related]
7. Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study.
Talbot DC; Ranson M; Davies J; Lahn M; Callies S; André V; Kadam S; Burgess M; Slapak C; Olsen AL; McHugh PJ; de Bono JS; Matthews J; Saleem A; Price P
Clin Cancer Res; 2010 Dec; 16(24):6150-8. PubMed ID: 21041181
[TBL] [Abstract][Full Text] [Related]
8. Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors.
Jeong W; Rapisarda A; Park SR; Kinders RJ; Chen A; Melillo G; Turkbey B; Steinberg SM; Choyke P; Doroshow JH; Kummar S
Cancer Chemother Pharmacol; 2014 Feb; 73(2):343-8. PubMed ID: 24292632
[TBL] [Abstract][Full Text] [Related]
9. Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia.
Park E; Gang EJ; Hsieh YT; Schaefer P; Chae S; Klemm L; Huantes S; Loh M; Conway EM; Kang ES; Hoe Koo H; Hofmann WK; Heisterkamp N; Pelus L; Keerthivasan G; Crispino J; Kahn M; Müschen M; Kim YM
Blood; 2011 Aug; 118(8):2191-9. PubMed ID: 21715311
[TBL] [Abstract][Full Text] [Related]
10. Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs.
Flory AB; Rassnick KM; Al-Sarraf R; Bailey DB; Balkman CE; Kiselow MA; Autio K
J Vet Intern Med; 2008; 22(1):164-71. PubMed ID: 18289305
[TBL] [Abstract][Full Text] [Related]
11. A combination chemotherapy protocol with dose intensification and autologous bone marrow transplant (VELCAP-HDC) for canine lymphoma.
Frimberger AE; Moore AS; Rassnick KM; Cotter SM; O'Sullivan JL; Quesenberry PJ
J Vet Intern Med; 2006; 20(2):355-64. PubMed ID: 16594594
[TBL] [Abstract][Full Text] [Related]
12. Use of epothilone B (patupilone) in refractory lymphoma and advanced solid tumors in dogs.
Meier V; Geigy C; Grosse N; McSheehy P; Rohrer Bley C
J Vet Intern Med; 2013; 27(1):120-5. PubMed ID: 23205945
[TBL] [Abstract][Full Text] [Related]
13. Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma.
Thamm DH; Vail DM; Post GS; Fan TM; Phillips BS; Axiak-Bechtel S; Elmslie RS; Klein MK; Ruslander DA
J Vet Intern Med; 2017 May; 31(3):872-878. PubMed ID: 28370378
[TBL] [Abstract][Full Text] [Related]
14. Thirteen-week dose-intensifying simultaneous combination chemotherapy protocol for malignant lymphoma in dogs.
Zenker I; Meichner K; Steinle K; Kessler M; Hirschberger J
Vet Rec; 2010 Nov; 167(19):744-8. PubMed ID: 21257510
[TBL] [Abstract][Full Text] [Related]
15. A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth.
Greenberger LM; Horak ID; Filpula D; Sapra P; Westergaard M; Frydenlund HF; Albaek C; Schrøder H; Ørum H
Mol Cancer Ther; 2008 Nov; 7(11):3598-608. PubMed ID: 18974394
[TBL] [Abstract][Full Text] [Related]
16. Changes in survivin messenger RNA level during cisplatin treatment in gastric cancer.
Ikeguchi M; Kaibara N
Int J Mol Med; 2001 Dec; 8(6):661-6. PubMed ID: 11712083
[TBL] [Abstract][Full Text] [Related]
17. Mutation of p53 Gene and Its Correlation with the Clinical Outcome in Dogs with Lymphoma.
Koshino A; Goto-Koshino Y; Setoguchi A; Ohno K; Tsujimoto H
J Vet Intern Med; 2016; 30(1):223-9. PubMed ID: 26678182
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors.
Tanioka M; Nokihara H; Yamamoto N; Yamada Y; Yamada K; Goto Y; Fujimoto T; Sekiguchi R; Uenaka K; Callies S; Tamura T
Cancer Chemother Pharmacol; 2011 Aug; 68(2):505-11. PubMed ID: 21079959
[TBL] [Abstract][Full Text] [Related]
19. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol.
Simon D; Nolte I; Eberle N; Abbrederis N; Killich M; Hirschberger J
J Vet Intern Med; 2006; 20(4):948-54. PubMed ID: 16955821
[TBL] [Abstract][Full Text] [Related]
20. A longitudinal study of ABC transporter expression in canine multicentric lymphoma.
Zandvliet M; Teske E; Schrickx JA; Mol JA
Vet J; 2015 Aug; 205(2):263-71. PubMed ID: 25475167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
